mRNA Cancer Vaccines Show Durable Results in Melanoma, Early Promise in Harder-to-Treat Tumors
Treatments based on the messenger RNA technology behind Covid-19 vaccines are demonstrating lasting efficacy against melanoma and showing early promise in pancreatic and brain cancers long considered beyond the reach of immunotherapy, researchers reported at a major oncology conference this week.
The advances arrive amid contradictory signals from Washington, where federal officials have simultaneously cut funding for mRNA vaccine programs while backing a new public-private cancer vaccine initiative. More than 130 studies presented at the American Society of Clinical Oncology meeting in Chicago this month addressed such efforts.
At the center of the field are Moderna (MRNA) and Merck (MRK), whose combination therapy pairing a checkpoint immunotherapy with a personalized mRNA cancer vaccine has kept melanoma in remission for five years. The companies are running nine mid- and large-scale trials across lung, kidney, bladder and pancreatic cancers. Roche (RHHBY) and BioNTech (BNTX) are also advancing their own programs. Market research firm Vision Research Reports estimates the personalized cancer vaccine market could reach $8.5 billion annually by 2034.
The clinical momentum comes despite significant policy turbulence. The Department of Health and Human Services cut $500 million from mRNA vaccine research programs earlier this year, yet the National Cancer Institute is simultaneously co-funding a $200 million public-private initiative to trial promising cancer vaccines. Researchers warn that drawing artificial distinctions between different applications of the same technology risks stunting progress. "If we don't do it, other countries will," said Dr. Elias Sayour of the University of Florida, an adviser to the NCI's cancer vaccine program.
Some of the most striking data stems from foundational work at leading cancer centers. Dr. Vinod Balachandran of Memorial Sloan Kettering began investigating mRNA as a potential treatment for pancreatic cancer after observing that a small subset of patients survived a disease widely assumed to be invisible to the immune system. A Phase 1 trial launched in 2019 testing chemotherapy, Roche's immunotherapy Tecentriq and a custom BioNTech mRNA vaccine found that seven of eight patients whose immune systems responded to the treatment remained alive up to six years later. A 260-patient global Phase 2 trial is now underway. "What a breakthrough it would be if mRNA was the technology that finally achieved an immune response that was clinically meaningful," said Dr. Robert Vonderheide, director of Penn Medicine's Abramson Cancer Center.
Researchers are also exploring mRNA's potential against glioblastoma, an aggressive brain cancer with a five-year survival rate of under 7%. Sayour is testing a vaccine that delivers clusters of lipid nanoparticles intravenously to rapidly mobilize the immune system. "If it can cure or even make a dent in glioblastoma," he said, "the implications for all forms of human cancer are extraordinary."